The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer.
Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.